Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VIVS, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
VIVS holds $8.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by the Company raise substantial doubt about its ability to continue as a going concern for at least one year following the date these condensed consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VIVS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Esousa Group Holdings LLC | 5%+ holder (13G) | 319,429 | 1.57% | 2026-06-30 |
| Vaidehi Joshi Director |
Insider | 58,821 | 0.29% | 2024-08-07 |
| Keith Murphy EXECUTIVE CHAIRMAN, Director · +143,731 options |
Insider | 26,053 | 0.13% | 2026-01-27 |
| Douglas Jay Cohen Director |
Insider | 20,898 | 0.10% | 2026-01-27 |
| Adam K Stern Director |
Insider | 19,899 | 0.10% | 2026-01-27 |
| Alison Tjosvold Milhous Director |
Insider | 19,899 | 0.10% | 2026-01-27 |
| David Gobel Director |
Insider | 15,000 | 0.07% | 2026-01-27 |
| Tony Serge Lialin Chief Commercial Officer · +40,000 options |
Insider | 10,000 | 0.05% | 2026-08-31 |
Share count 20,281,495 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VIVS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →